|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: BARCLAYS GLOBAL INVESTORS NA /CA/, SC 13G/A, 2000-10-06 |
Next: SANGSTAT MEDICAL CORP, 8-K, EX-99.1, 2000-10-06 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 4, 2000
SANGSTAT MEDICAL CORPORATION (Exact name of registrant as specified in its charter)
|
|
|
|
|
|
6300 Dumbarton Circle
Fremont, California 94555
(Address of principal executive offices including zip code)
510-789-4300
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Item 5. Other Matters
On October 4, 2000, the Company issued a press release announcing that it has obtained an exclusive license to the technology for a novel cyclosporine capsule formulation. The Company expects to file a Marketing Authorization Application (MAA) with the Medicines Control Agency in the United Kingdom by mid-2001 and plans to withdraw its MAA in the UK for its current cyclosporine capsule product, known as Sang-2000, in favor of this newer formulation.
The foregoing changes are discussed in greater detail in the Company's press release, a copy of which is filed herewith as exhibit 99.1.
Item 7. Financial Statements and Exhibits
(a) Financial statements of business acquired. - Not applicable
(b) Pro forma financial information. - Not applicable
(c) Exhibits
| Exhibit No | Description |
| 99.1 | Press Release dated October 4, 2000 |
SIGNATURES
Pursuant to the requirement of the Security Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 6, 2000
| SANGSTAT MEDICAL CORPORATION |
| By: | /s/ Stephen G. Dance |
|
| |
| Stephen G. Dance | |
| Senior Vice President, Finance |
EXHIBIT INDEX
| Exhibit No | Description |
| 99.1 | Press release dated October 4, 2000. |
|
|